Claudia Robertson Lab

Media Component
Dr. Claudia Robertson

The Robertson Lab’s research has been directed at developing new methods for monitoring the brain in the intensive care unit, and studying treatments that might improve outcome.

The clinical team is participating in a major multi-site NIH funded project that has enrolled 3,000 patients with traumatic brain injury (TBI) and followed them for a year after injury with assessments of blood based biomarkers, advanced MRI imaging and a neurological assessment. Now that enrollment is complete in this study, the group has obtained additional funding from NIH and DoD to continue to follow these patients beyond one year to determine long-term consequences of brain injury.

The team is also participating in an NIH funded clinical trial, called BOOST-3, which will evaluate the usefulness of monitoring and treating brain oxygenation after severe traumatic brain injury and a DoD funded observational study examining the frequency and consequences of spreading depolarizations in the brain after injury.

In addition, the team is participating in a multi-site DoD funded project that will validate the Abbott Point of Care measurement of two promising blood biomarkers of brain injury, GFAP and UCHL1, on the i-STAT platform.  

Finally, Dr. Robertson is participating in the planning a TRACK-TBI NET, which will be a DoD funded phase two clinical trials network for testing potential drug treatments for TBI using an adaptive trial design and novel outcome assessments.


  • Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI)
  • Spreading Depolarizations II (SDII): Development and Validation of Spreading Depolarization Monitoring for TBI Management 
  • Brain Oxygen Optimization in Severe Traumatic Brain Injury - Phase 3 (BOOST-3)
  • Clinical Evaluation of the i-STAT TBI Test